Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OGESTREL 0.5/50-28 vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases cervical mucus viscosity and alters endometrial development.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Prevention of pregnancy,Treatment of moderate acne vulgaris (females ≥15 years, for formulations with at least 30 mcg ethinyl estradiol and norgestimate/desogestrel)
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet (norgestrel 0.5 mg/ethinyl estradiol 50 mcg) orally once daily for 28-day cycle.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Norgestrel: ~45 hours (range 24-56 h) enabling once-daily dosing; Ethinyl estradiol: ~17 hours (range 10-27 h).
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Norgestrel and ethinyl estradiol are metabolized primarily via cytochrome P450 3A4 (CYP3A4) in the liver; undergo first-pass metabolism; ethinyl estradiol also undergoes conjugation (sulfation, glucuronidation).
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Renal: 50-60% as metabolites (glucuronide and sulfate conjugates of norgestrel and ethinyl estradiol); Fecal: 30-40% via biliary elimination; Unchanged drug: <1%.
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Norgestrel: ~97% bound to sex hormone-binding globulin (SHBG) and albumin; Ethinyl estradiol: ~98% bound to albumin, with 2% free (active).
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Norgestrel: ∼4 L/kg (range 3-5 L/kg), indicating extensive tissue distribution; Ethinyl estradiol: ∼2 L/kg (range 1.5-3 L/kg), reflecting distribution to reproductive tissues and liver.
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Oral: Norgestrel ~90-100% (high first-pass metabolism but minimal systemic loss); Ethinyl estradiol ~40-50% due to first-pass metabolism (conjugation in gut wall and liver).
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No dose adjustment required for mild to moderate renal impairment. Not recommended in severe renal impairment (Cr Cl <30 m L/min) or ESRD due to lack of safety data.
No data available for fictional drug ALYACEN 777.
Contraindicated in acute hepatic disease or Child-Pugh class B and C cirrhosis. For mild hepatic impairment (Child-Pugh A), use with caution; no specific dose adjustment studied.
No data available for fictional drug ALYACEN 777.
Not indicated for children; use only after menarche. Postmenarcheal adolescents: same as adult dosing (one tablet daily) once menses established.
No data available for fictional drug ALYACEN 777.
Not indicated for women ≥65 years; no geriatric-specific dosing recommended. Consider alternative therapies due to increased thrombosis risk and reduced bone density with prolonged use.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (>35 years) and number of cigarettes smoked. Women over 35 who smoke should not use this product.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Thrombotic disorders (venous thromboembolism, arterial thromboembolism, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate/lipid effects,Headache/migraine,Vaginal bleeding irregularities,Depression,Hereditary angioedema
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Known or suspected pregnancy,Current or history of venous thromboembolism (VTE) or arterial thromboembolism (ATE),Active liver disease or hepatic tumors,Undiagnosed abnormal genital bleeding,Known or suspected breast cancer or other estrogen-sensitive neoplasia,Hypersensitivity to any component,Cigarette smoking in women >35 years,Uncontrolled hypertension,Migraine with aura in women ≥35 years
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically negligible. Avoid high-fat meals if taking with a progestin-only pill (not applicable here).
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
No increased risk of birth defects has been observed in clinical studies for norgestrel/ethinyl estradiol. Use during pregnancy is contraindicated as hormonal contraceptives are not indicated during gestation. There is no evidence of teratogenicity when inadvertently taken during early pregnancy.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Small amounts of norgestrel and ethinyl estradiol are excreted in breast milk. M/P ratio not established. Can reduce milk production and quality. Use is generally not recommended during breastfeeding; alternative methods should be considered.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
Not applicable; contraindicated in pregnancy. No pharmacokinetic studies during pregnancy; no dose adjustment recommendation exists.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
OGESTREL 0.5/50-28 contains norgestrel 0.5 mg and ethinyl estradiol 50 mcg. Its higher estrogen dose (50 mcg) increases thromboembolic risk; avoid in smokers over 35. Use as emergency contraception off-label. Missed pill management: if one pill missed, take as soon as remembered; if two or more missed, use backup contraception. Withdrawal bleeding typically occurs during the 7 placebo pills.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one pill daily at the same time; do not skip doses.,During the 7 placebo pills, you will have a withdrawal bleed; this is normal.,Use backup contraception (e.g., condoms) if you miss 2 or more pills.,Do not smoke while taking this medication, especially if over age 35.,Report any signs of blood clots: leg pain/swelling, chest pain, shortness of breath, sudden headache or vision changes.,This medication does not protect against HIV or other sexually transmitted infections.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OGESTREL 0.5/50-28 vs ALYACEN 777, answered by our medical review team.
OGESTREL 0.5/50-28 is a Oral Contraceptive that works by Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases cervical mucus viscosity and alters endometrial development.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OGESTREL 0.5/50-28 and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OGESTREL 0.5/50-28 is: One tablet (norgestrel 0.5 mg/ethinyl estradiol 50 mcg) orally once daily for 28-day cycle.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OGESTREL 0.5/50-28 and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OGESTREL 0.5/50-28 is classified as Category C. No increased risk of birth defects has been observed in clinical studies for norgestrel/ethinyl estradiol. Use during pregnancy is contraindicated as hormonal contraceptives are no. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.